Sustainability | February 20, 2024
Biocon included in S&P Global Sustainability Yearbook 2024
Sustainability is integral to Biocon's business purpose
Sustainability is integral to Biocon's business purpose
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Submission to be reviewed under FDA real-time oncology review and Project Orbis
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Subscribe To Our Newsletter & Stay Updated
